Antisense approaches for the treatment of cancer.
Monia
B P
BP
Isis Pharmaceuticals, Carlsbad, California, USA. bmonia@isisph.com8.0
Holmlund
J
J
Dorr
F A
FA
D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D019254:Genes, bcl-2 / Q000502:physiology; D020570:Genes, myb / Q000502:physiology; D011905:Genes, ras / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D020319:Oligodeoxyribonucleotides, Antisense / Q000627:therapeutic use; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors; D012333:RNA, Messenger / Q000032:analysis; D013873:Thionucleotides / Q000627:therapeutic use
D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D013873:Thionucleotides; C108494:ISIS 3521; C099587:ISIS 5132; D019908:Proto-Oncogene Proteins c-raf; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C